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ABSTRACT 
Background 
Anxiety disorders are common and a substantial proportion of patients do not respond to 
conventional treatments such as SSRIs or CBT. Capsulotomy is a neurosurgical treatment for 
treatment refractory patients with Obsessive-Compulsive Disorder (OCD) and other anxiety 
disorders. The aim of this thesis was to assess the long-term efficacy and safety of capsulotomy. 
 
Methods and results 
In Study I, 26 consecutive patients who underwent capsulotomy from 1975-1991 were followed 
after a mean of 13 years. Main diagnoses were Generalized Anxiety Disorder (n=13), Panic 
Disorder (n=8) and Social Phobia (n=5). Mean Brief Scale of Anxiety score dropped 
significantly from preoperative 22 to 10 at long-term. Seven patients had postoperative 
problems in the domains of executive functioning, apathy or disinhibition. Mean weight gain in 
the first postoperative year was almost 10 kg. Study II and III were substudies of Study I.  
 
In Study II the capsulotomy lesion size and localization in the anterior-posterior plane was 
analyzed. We could not replicate previous findings of a common anatomical denominator in the 
right-sided capsule in patients responding to the treatment. In Study III, we used a self-rated 
personality inventory, the Karolinska Scales of Personality, to describe changes pre- to 
postoperatively in self-rated personality. Patients were significantly less anxiety prone at 
follow-up. 
 
Study IV was a long-term follow-up of 25 consecutive OCD capsulotomies performed 1988 -
2000. Mean Y-BOCS was 34 preoperatively and dropped to 18 at long-term follow-up 
(p<0.0001). Only 2 patients achieved remission from OCD without substantial side effects. 
Several neurosurgical complications related to radiosurgery were reported.Two patients were 
severely disinhibited postoperatively. Ten patients were considered to suffer from significant 
problems in the area of executive functioning, apathy or disinhibition. Global functioning did 
not return to normal after surgery. Lesion size did not correlate significantly with efficacy or 
adverse effects. 
 
Conclusions 
Capsulotomy is effective in reducing symptoms in both OCD and other anxiety disorders. 
About every third patient experienced apathy, executive problems or disinhibition at long-term 
follow up, therefore we conclude that capsulotomy is not a safe procedure. We could not 
identify lesion characteristics that could explain the differences in outcome. We could not 
confirm the hypothesis of a certain right-sided lesion as a prerequisite for response to 
capsulotomy. 
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1 ABBREVIATIONS 
Ac Anterior commissure 
ACC Anterior cingulate cortex 
CBT Cognitive-behavioral therapy 
CSTC Cortico-striato-thalamo-cortical circuitry 
CT Computed Tomography 
EAD The Execution, Apathy and Disinhibition Scale 
FrSBe Frontal Systems Behavior Scale™ 
GAD Generalized anxiety disorder 
Gy Gray 
KSP Karolinska Scales of Personality 
MRI Magnetic resonance imaging 
NMD Neurosurgery for mental disorders 
OCD Obsessive-compulsive disorder 
OFC Orbitofrontal cortex 
PANDAS Pediatric autoimmune neuropsychiatric disorders associated with 
streptococcal infections 
Pc Posterior commissure 
RCT Randomized controlled trial 
SD Standard deviation 
SSRI Selective serotonin reuptake inhibitor 
WCST Wisconsin Card Sorting Test 
Y-BOCS Yale-Brown Obsessive-Compulsive Scale 
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2 INTRODUCTION 
2.1 WHY THIS? 
It was in my fifth year in medical school that I first heard of capsulotomy. Like most 
people, I had a somewhat vague idea about neurosurgery for psychiatric illnesses being 
something evil that went on back in the days before I was born. I had also seen Milos 
Forman’s classic film One Flew Over the Cuckoo’s Nest and remembered that they did 
some nasty stuff to Jack Nicholson. After listening to the late Professor Per Mindus’ 
lecture on OCD, I had the opportunity to sit in on a couple of his consultations. Mindus 
was the psychiatrist in charge of the neurosurgical treatments for psychiatric disorders. 
The patients with Obsessive-Compulsive Disorders immediately spellbound me. A few 
years later I had my first position as a junior doctor at the Psychiatric Clinic of the 
Karolinska Hospital and met Per Mindus again. I met one of his capsulotomy patients 
during my regular clinical work (who later turned out to be one of the patients in Study 
IV of this thesis) and contacted Prof. Mindus which was to be the start of our 
collaboration. I soon became aware of the controversy surrounding the treatment. In the 
last year of his life, this debate was also given attention in the public media. As a 
consequence of this, we received funding from the National Board of Health and 
Welfare in order to evaluate capsulotomy as a treatment for anxiety disorders.  
 
Neurosurgery for mental disorders has always been controversial (1, 2). Capsulotomy is 
a neurosurgical procedure for intractable OCD and anxiety and has its historical roots 
in lobotomy, a treatment that for many is a symbol for medical barbarism. Capsulotomy 
has been used at the Karolinska Hospital since the 1950s and was introduced by the 
legendary neurosurgeon Lars Leksell. It has been described as an effective and safe 
treatment (3) for primarily OCD but also for other anxiety disorders.  
 
When I started this research I had the notion that it was indeed a safe and effective 
treatment but during my work I became aware that the evidence for capsulotomy was 
not as solid as I had imagined. The present thesis is the result of the research that 
emerged from my desire to find out more about the efficacy and safety of capsulotomy 
as a treatment for severely ill anxiety patients.  
 
Before we look at what capsulotomy is and the evidence for the procedure, let us 
recapitulate the clinical picture and neuroanatomy of the anxiety disorders.  
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2.2 ANXIETY DISORDERS 
2.2.1 Clinical picture 
Anxiety disorders are among the most prevalent psychiatric disorders (4) and often 
strike in childhood or early adulthood. Etymologically, anxiety has complex origins 
including the Latin anxietas, a lasting state of fearfulness, angor, intense fear, and the 
French angoisse, a more acute panic-like state (5). Anxiety is used both in everyday 
language to describe tension or anguish that is a part of normal life and to label a 
psychiatric symptom common not only in anxiety disorders but also in mood disorders. 
The anxiety disorders according to the Diagnostic and Statistical Manual of Mental 
disorders (DSM-IV) (6) include social phobia, panic disorder, generalized anxiety 
disorder, post-traumatic stress disorder, obsessive-compulsive disorder and specific 
phobia. Current evidence-based treatments such as SSRIs or Cognitive-Behavioral 
Therapy (CBT) are effective treatments for most patients (7). This thesis focuses on a 
neurosurgical treatment, capsulotomy, for anxiety patients that did not respond to 
conventional treatment, i.e. who were treatment refractory. 
 
• Social phobia concerns extreme fear of being in the center of social attention, 
or the object for social evaluation. As a result, public speaking, social 
gatherings, confronting superiors, or contacts with potential sexual partners are 
either avoided or endured with intense fear or panic.  
 
• Panic disorder includes panic attacks that are sudden surges of physiological 
symptoms (heart palpitation, sweating, difficulties breathing, shakiness, 
dizziness, etc.) and feelings (derealization, fear of losing control or dying) that 
come unprovoked, and then subside within some ten minutes. Often patients 
start worrying about further attacks, thus developing anticipatory anxiety and 
avoidance of situations in which he or she would be vulnerably exposed and 
helpless in the event of an attack. 
 
• Generalized Anxiety Disorder (GAD) is characterized by constant anxiety, 
which is driven by excessive and more or less chronic worry about different life 
circumstances, e.g., economical matters, health, and work or school 
performance. The worry is impossible to control, and there is an inability to 
relax. This makes a person with GAD tense, worked up, hypervigilant, and 
chronically exhausted. 
 
• Obssessive-Compulsive Disorder (OCD) is characterized by unwanted 
intrusions (obsessions) and ritualized and repetitive behavior (compulsions).  
 
Robert Burton beautifully depicts what today would be called OCD in his “Anatomy of 
Melancholy” from 1632 (8): “If he be in a silent auditory, as at a sermon, he is afraid he 
shall speak out unawares, something undecent, unfit to be said …Another dares not go 
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over a bridge, come near a pool, rock, steep hill, lie in a chamber where cross-beams 
are, for fear he be tempted to hang, drown, precipitate himself …”. Freud writes that 
obsessional neurosis, "is unquestionably the most interesting and rewarding subject of 
analytic research, but as a problem it is still unmastered [unbezwungen]"(9).  
 
There is accumulating evidence (10) from comorbidity, family and neuroimaging 
studies that OCD should form its own diagnostic group (OCD spectrum disorders) with 
similar disorders such as Body Dysmorphic Disorder, hypochondriasis and 
trichotillomania. 
 
Two clinical vignettes are presented as examples of the clinical problems this thesis 
tries to address. 
 
 
 
2.2.2 What is treatment refractory? 
The inclusion criteria for surgery are described in section 4.1.2. In the studies of this 
thesis, patients were operated on from 1975-2000 and during this time important 
progress in the treatment of anxiety disorders has been made. What is considered to be 
treatment refractory will therefore be different across this time-span. In the 1980s 
clomipramine and SSRIs became standard treatments for OCD and other anxiety 
disorders. Before 1980 there were no randomized-controlled trials for clomipramine 
Ms A describes herself as having been an insecure and shy child. At age 27 
her insecurity around people began to increase. She soon developed severe 
avoidance of all social situations, including the use of public transportation. 
Treatments included insight-oriented psychotherapy, clomipramine, 
benzodiazepines, behavioral therapy and neuroleptics. By age 34 she is 
unable to continue her job as a nurse’s assistant and is given a disability 
pension. 
 
Ms. S:s OCD started in her early twenties, following the birth of her first child. 
Her main symptoms are contamination fears and cleaning rituals that have 
taken over her life. When Ms. S has to defecate, she uses 8 rolls of toilet paper 
and showering can last over ten hours due to extensive cleaning rituals She 
checks locks, the stove and electrical appliances excessively. Her Yale-Brown 
Obsessive-Compulsive Scale rating score is 35, indicating extreme OCD. 
Cognitive-behavioral and pharmacological treatment trials have been without 
avail. 
 
Both patients were referred to the Karolinska Hospital for evaluation for 
capsulotomy. Should we recommend capsulotomy for them? What is the 
potiental efficacy of such a treatment and are there any adverse effects that 
Ms E and Ms A may experience?  
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(11), the first effective medication for OCD. Therefore it is unclear how the 
refractoriness was assessed before that time. Treatment refractoriness is considered to 
be a criterion for capsulotomy and has been defined as “current treatment options tried 
systematically for at least five years have either been without appreciable effect on the 
symptoms, or must be discontinued due to intolerable side effects” (12). This is also the 
definition that has been applied at our site. In some studies a more operationalized 
definition of which treatments the patient is refractory to has been applied (13). 
Without a more precise definition treatment refractory may be considered to be a term 
without much validity. Pallanti (14) therefore proposed a definition of levels of 
response and non-response in OCD to help define the term. Since this classification 
was published very recently, it was not used in our studies. 
 
2.2.3 Neuroanatomy of OCD and anxiety 
In a meta-analysis of functional neuroimaging in OCD from 2004, Whiteside et al (15) 
found consistent differences in between OCD patients and controls in the orbital gyrus 
and the head of the caudate nucleus. This is consistent with other reviews (16) claiming 
relative hyperactivity of OFC (orbitofrontal cortex, includes the orbital gyrus), ACC 
(anterior cingulate cortex) and the caudate nucleus both in resting state and in symptom 
provocation. There is also emerging data (17) supporting the view that different OCD 
symptom groups (dimensions) have distinct neural correlates. In line with those 
findings, OCD has been suggested (18) to be related to the emotion disgust whereas 
fear is a dominant emotion in the other anxiety disorders. This makes sense particularly 
for the washing/contamination subtype since disgust can been seen as having an 
evolutionary function of contamination and illness avoidance.  
 
Another body of research that points to basal ganglia pathology in OCD are the 
Pediatric autoimmune neuropsychiatric disorders associated with streptococcal 
infections (PANDAS) which is a recently described syndrome (19, 20) of rapid onset 
neuropsychiatric symptoms such as OCD or tics in primarily children infected with 
common streptococcal infection. PANDAS are, despite a certain controversy on the 
validity of the diagnosis (21), considered to be an autoimmune disease affecting the 
basal ganglia (22). A MRI study of children with PANDAS demonstrated enlarged 
caudate, putamen and globus pallidus, suggesting regional inflammatory changes in the 
regions that appear to be associated with OCD symptomatology (23). Generally, 
neuroimaging results support a proposed model of pathology within the cortico-striato-
thalamo-cortical (CSTC) circuitry. To elaborate, caudate pathology has been proposed 
as a mechanism of CSTC dysfunction (24) This caudate malfunctioning is thought to 
lead to ineffective thalamic gating, which then results in hyperactivity of the OFC and 
ACC. Since the internal capsule, the anatomical target of capsulotomy, contains nerve 
fibers connecting the thalamus to parts of the prefrontal cortex it is a logical target for 
surgery intended to alter functioning in the CSTC circuitry. Moreover, the extended 
ventral striatum, including the nucleus accumbens has gained increased attention (25-
27). Nucleus accumbens, situated just beneath the internal capsule, holds a key position 
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receiving input from e.g. the amygdala and projecting to the striatum, thalamus and the 
prefrontal cortex. Dopamine is the major transmittor in the nucleus accumbens (28). 
 
Much research in neuroanatomical models of fear and anxiety focuses on the role of the 
amygdala. The amygdala is an almond-shaped structure located in the anterior part of 
the temporal lobe and is a considered to play an important role in the detection of threat 
and the activation of a fear response (29). The fear response will prepare for motor 
action, increase arousal and increase attention to fearful stimuli (30). LeDoux (31) has 
proposed that fear activation can operate by a fast subcortical “low road” afferent 
inflow to the amygdala without signals passing through the cortex, thus enabling us to 
respond before the feared stimulus is consciously perceived. The amygdala has 
connections to the prefrontal cortex and CSTC circuits affecting the inflow of 
information through the thalamus. The medial prefrontal cortex, including the OFC and 
ACC, has been proposed to exercise top-down control over the amygdala (32, 33). 
More specifically, panic disorder has been associated with amygdala 
hyperresponsitivity and impaired top-down suppression of the amygdala from the 
medial prefrontal cortex. In social phobia there is also some evidence of amygdala 
activation during symptom provocation (34).  
 
 
 
Figure 1. Anatomical structures and surgical targets for neurosurgery for mental disorders. 
 
2.2.4 The internal capsule 
The internal capsule (capsula interna) is a white matter tract containing several 
important fiber systems. The pyramidal tract (motor fibers) passes through the posterior 
part of the internal capsule. The anterior portion of the capsule, where capsulotomy 
lesions are placed, contains no motor fibers. The anterior part, crossing the striatum, 
contains the thalamic radiation with fibers connecting the thalamus to the prefrontal 
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cortex. The anterior capsule also contains the frontopontine fibers from the 
corticopontine tracts projecting from the prefrontal cortex to the pontine nuclei, which 
in turn project into the cerebellum. These fibers are intermingled with frontothalamic 
fibers. Smaller number of fibers from the nucleus caudatus to the nucleus lentiformis 
traverse the anterior limb (35). Thus, the lesions created in capsulotomy affect a 
number of interconnected regions, most importantly the prefrontal cortex. 
 
2.3 NEUROSURGERY FOR MENTAL DISORDERS 
2.3.1 A brief history of neurosurgery for anxiety and OCD 
“Psychosurgery”, now often referred to as Neurosurgery for mental disorders (NMD), 
is assumed to have been used in the form of trephining in ancient cultures such as the 
Incas. The first account of ablative NMD is from the Swiss psychiatrist Gottlieb 
Burckhardt who reported on the outcome of six psychotic patients undergoing cerebral 
cortical extirpation (“topectomy”) in 1889 (36). Burckhardt reported modest outcomes 
and some severe complications including perioperative death. He was criticized for 
performing the operations and many arguments in that debate are strikingly similar to 
current ones. Burckhardt leaned more towards the principle of Melius anceps remedium 
quam nullum (Better an uncertain remedy than none at all) than the Primum non nocere 
(First, do no harm) of his opponents. The first 20 lobotomies were performed in 1935 
by Almeida Lima and the Nobel laureate Egaz Moniz. The American neurologist 
Walter Freeman and colleagues quickly picked up on these news and lobotomy soon 
became a common treatment for mentally ill people from different diagnostic groups. 
The history of early psychosurgery is indeed very interesting, for reviews see e.g. 
Feldman et al and others (37-39).  
 
One of the turning points in the use of lobotomy was the Swedish psychiatrist Gösta 
Rylander’s research (40) showing gross changes in personality following frontal lobe 
surgery. At the 1947 meeting of the Association for Research in Nervous and Mental 
Disease he presented data on changes in personality after lobotomy (41, 42). He quoted 
relatives to patients saying “she is with me in body but her soul is in some way lost”, a 
story that rapidly circulated (38). At the same time it is important to remember that 
there was evidence supporting the efficacy of lobotomy (43) and that this was at a time 
when there were virtually no effective treatments for the many patients filling the 
asylums. This could explain the enthusiasm that met new treatments such as lobotomy 
and psychoanalysis. Sweden is one of the countries with the most widely spread uses of 
lobotomy with some 4500 operations performed from 1944-1966 (44).  
 
There has been a debate (45, 46) on whether or not lobotomy patients should be 
financially compensated. In 1996 the Norwegian parliament decided to pay 
100,000 NOK to each patient (47), while the Swedish authorities decided not to offer 
any compensation.  
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Capsulotomy, where the bilateral lesions are produced in the anterior limb of the 
internal capsule, was first briefly reported by Talairach (48) in 1949. Leksell (49) 
further, and independently, developed the method and termed it bilateral capsulotomy. 
Originally, the rationale for selecting the internal capsules as targets was based on 
investigations by Meyer and Beck (50) in 1954 who at autopsy of patients subjected to 
lobotomy demonstrated that the common anatomical denominator of good outcome 
comprised parts of the anterior internal capsules. Other procedures such as 
cingulotomy, currently used for depression and OCD (13), subcaudate tractotomy (51) 
and limbic leucotomy (52) were developed during the same time period. 
 
 
 
 
 
Figure 2. Gösta Rylander (1903-1979), the first professor of forensic psychiatry in Sweden. He 
was among the first to raise doubts on the widespread use of lobotomy.  
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Figure 3. From the front page of the New York Times, June 7 1937.  
 
 
 
 
  11 
Figure 4. Axial MRI, capsulotomy 
lesions bilaterally medial to the 
putamen. 
 
2.3.2 Capsulotomy 
Capsulotomy is a neurosurgical procedure where lesions in the anterior part of the 
internal capsules (Figure 4) are produced either by heating (thermocapsulotomy) or by 
converging beams of gammaradiation (radiosurgery). The methods are described in 
detail in section 4.2. 
 
 
 
 
2.3.2.1 Is Capsulotomy an evidence-based treatment for anxiety and OCD?  
All NMD studies have been uncontrolled, as sham (placebo) operations for obvious 
reasons have not been applied. In systematic evaluations (such as the Cochrane 
Collaborations’) of the evidence base of interventions, non-controlled studies are 
considered as having low evidence and thus capsulotomy, in principle, cannot be 
considered to be an evidence based treatment in the most orthodox sense. The reported 
efficacy in most studies is satisfactory, ranging from 40 percent of patients with 
permanent improvement (53) to 73 percent at least “much improved” (54). In the 
largest study to date, Herner in 1961 (53) reported on 116 capsulotomy patients of 
different diagnostic categories including 15 anxiety and 18 OCD cases. Fourteen of the 
OCD patients included in the study had a “regression or disappearance of symptoms”. 
Six of the anxiety patients had regression of symptoms. Bingley (55) reported on the 
outcome of thermocapsulotomies in OCD patients and reported much improvement or 
that the patient was free from symptoms in 25 of 35 cases. Working capacity also 
increased and there was no evidence of adverse effects on personality or cognition. 
Rylander (56) reported on the outcome of both thermocapsulotomy and radiosurgery in 
52 OCD and anxiety patients with favorable outcome. All patients but 3 had improved 
at follow-up. No permanent side effects were reported. In a congress proceeding from 
1981, Burzaco reported (54) on the outcome of capsulotomy in 85 cases with OCD and 
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73 % were classified as “much improved or symptom free”. Lippitz (57) studied the 
lesion morphology in a sample of 29 OCD capsulotomy patients of whom 16 had a 
symptom score reduction of at least 50 %. A recent study (58) reported that 8 of 15 
patients had at least a 33% OCD symptom reduction at follow-up. Thus, most of the 
data concerns OCD patients whereas the evidence for efficacy in other anxiety 
disorders is very sparse.   
 
2.3.3 Is Capsulotomy safe? 
The reported rate of adverse effects varies considerably. Herner (53) noted that in a 
group of 116 capsulotomy cases, frontal lobe deficit syndrome was obvious at follow-
up in 30 percent. Table 1 displays the severity of the side effects in different diagnoses. 
Adverse effects in Herner’s sample and in a study by Kullberg (59) included fatigue, 
emotional blunting, emotional incontinence, indifference, low initiative, disinhibition, 
and impaired sense of judgment. A few studies have compared different neurosurgical 
methods. Kullberg (59) noted that cingulotomy produced fewer adverse effects 
(transient confusion and affective deficit) in the immediate postoperative phase than 
capsulotomy. In another study (56), conventional thermocapsulotomy was compared to 
Gamma Knife capsulotomy (radiosurgery) in OCD patients. The efficacy was 
satisfactory in both groups, but in the radiosurgery group there were no signs of 
postoperative confusion and disorientation, a common temporary adverse effect after 
thermocapsulotomy. As mentioned previously, Bingley (55) and Rylander (56) did not 
report any permanent adverse effects in their studies. In Mindus’ prospective one-year 
follow-up study of 24 thermocapsulotomies (60), favorable results were reported in 
general. Seven patients reported excessive fatigue postoperatively but this was not 
interpreted as a sign of frontal lobe syndrome. In the most recent study (58), one of 15 
patients suffered from a permanent “behavior disorder” following postoperative brain 
edema. No other permanent side effect was reported and on neuropsychological 
screening no cognitive deficit was found although only 6 patients had been followed for 
12 months.  
 
2.3.4 Limitations of the previous studies 
• As mentioned earlier the most important limitation of earlier studies is the lack 
of control treatment. The reason for this is the difficulty in designing a control 
treatment since it would be difficult or even impossible to perform sham 
(placebo) surgery.  
 
• Given most investigators involvement in patient selection, treatment and 
follow-ups, there is a potential investigator bias. The patients of course also 
share this. Moreover, all of the mentioned studies come from highly specialized 
centers that might have a self-interest in the publication of favorable results. 
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• Many of the cited studies are published as dissertations (53, 60), book chapters 
or congress proceedings (54-56, 59) that may not have undergone the same 
peer-review as commonly is the case in scientific journals. 
 
• Much of the evidence (53-56, 59, 60) for the efficacy of capsulotomy comes 
from operations performed long ago. The value of the evidence for current 
patient populations can be questioned since diagnostic procedures, surgical and 
radiological methodologies have advanced. New treatments that are added over 
the years will change what population of treatment refractory patients that are  
candidates for surgery.  
 
• Most NMD studies to date are short-term studies and have not assessed 
potential adverse effects in a systematic way.  
 
Despite that capsulotomy has been characterized as an effective and safe treatment for 
OCD and other anxiety disorders, there are important shortcomings in the 
documentation. Therefore, the conclusion is that the efficacy and safety of the 
procedure must be further investigated.  
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Figure 5. Side effects in Herner’s capsulotomy study (53). 
 
 
 
 
Figure 6. Portrait of Torsten Herner (1908-1996, left) and neurosurgical pioneer Lars Leksell 
(1907-1986, right), with one of his inventions, the stereotactic frame. 
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3 GENERAL AIMS 
a. To assess the efficacy of capsulotomy in two consecutive samples of anxiety 
disorder and OCD, respectively, at one-year and long-term follow-up. Efficacy 
was measured as changes in symptom rating scales, ratings of impairment, 
improvement and global functioning.  
 
b. To assess the long-term safety of capsulotomy samples through clinical 
observations, self- and family ratings of personality and frontal lobe deficit 
behavior and neuropsychological assessment. 
 
c. To relate the outcome to characteristics of the neurosurgical lesion. 
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4 METHODS 
4.1 PATIENTS 
4.1.1 Patient selection 
Treatment refractory patients that had undergone capsulotomy for OCD or other 
anxiety disorders at the Karolinska University Hospital from 1975 to 2000 were 
included in Study I-IV. 
 
4.1.2 General inclusion criteria for capsulotomy 
Inclusion criteria for capsulotomy (12, 61) were, in sum:  
• Chronic illness (duration ≥5 years); 
• The illness causes substantial suffering and considerable reduction in 
psychosocial functioning; 
• Current  available psychological and pharmacological treatment options tried 
systematically for at least five years without substantial effect;  
• Informed consent. 
 
4.1.3 Study I-III 
All 26 (15 women and 11 men) consecutive patients with anxiety disorders other than 
OCD who were treated with bilateral thermocapsulotomy between 1975 and 1991 at 
the Karolinska University Hospital, Stockholm, Sweden, were included in Study I. Of 
these three were deceased, two were too somatically ill to be interviewed, one refused 
participation, and two patients did not show up. Thus, eighteen patients were available 
for long-term follow-up. Mean age at first capsulotomy was 41.4 years (range 31-54, 
SD 6.5). Mean age at long-term follow-up was 54.5 years (range 42-71, SD 8.3, n=18). 
Mean duration of illness at the time of surgery was 18.0 years (SD 9.2, range 5-40). 
Twelve of these 18 patients were examined with MRI at long-term follow-up. One 
dataset was lost, therefore 11 patients constituted the sample of Study II. Sixteen of the 
18 patients that were evaluated at long-term had complete sets of the Karolinska Scales 
of Personality and constituted the sample in Study III. 
 
4.1.4 Study IV 
All twenty-five OCD patients subjected to capsulotomy from 1988 to 2000 at the 
Karolinska University Hospital in Stockholm were included in this study. Fourteen of 
the patients were women, 11 were men. The mean age at first capsulotomy was 41 
years (SD 11.0, range 25-68) and the disorder duration at the time of surgery was 21 
years (SD 8.3, range 8-40). The mean age at long-term follow-up was 52 years (SD 
12.0, range 33-83). Of the 25 patients, two had died at the time of long-term follow-up.  
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4.2 NEUROSURGICAL METHODS 
 
4.2.1 Thermocapsulotomy 
Thermocapsulotomy is conventional stereotactic surgery where burr holes are made 
slightly anterior to the coronal suture and lesions are produced using an 
electrode with a diameter of 1.5 mm and a 10 mm bare tip with heating to 60° C during 
60 seconds. In Study I-II lesions were produced with monopolar (9 operations) or 
bipolar (20 operations) electrodes. In the latter case, the inter-electrode distance was 6 
mm. The intended height of the lesions was 18-20 mm, and for bipolar electrodes the 
medio-lateral extension was approximately 8 mm. Only monopolar electrodes were 
used in Study IV. The estimated height of the lesions in study IV, i.e. their dorso-
ventral extension, was 12-20 mm. In Study IV, one patient had prior to her bilateral 
themocapsulotomy been subjected to trial Deep Brain Stimulation, to our knowledge 
the first OCD patient who had undergone such treatment. Based on data by Lippitz et al 
(57, 62), four patients had a unilateral right-sided thermocapsulotomy, in one case 
followed by a second one.  Surgery was performed under local anesthesia with 
moderate sedation. 
 
4.2.2 Radiosurgery 
Radiosurgery, also referred to as Gamma Knife® surgery, was performed in a subgroup 
of patients in Study IV using different models of the Leksell Gamma Knife® unit 
(Elekta AB, Stockholm, Sweden, Figure 7). Lesions are produced (without opening the 
skull), by converging beams of gamma radiation, much like sunbeams through a 
looking glass. Round collimators (4 mm) were selected. Doses of 160-200 Gy were 
applied. Five patients received 200 Gy in 3 isocenters bilaterally. The radiobiology of 
these lesions has been discussed by Kihlström and collegues (63, 64) and they 
concluded that the larger the irradiated volume, the less predictable the resulting lesion 
volume. Further, three isocenters was not recommended (63). It seems that the five 
patients in Study IV receiving 200 Gy in three isocenters were subjected to higher 
doses of radiation than in hindsight would be recommended.  
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Figure 7. Section of the Leksell Gamma Knife®. Cobalt 60 (light blue) emits gamma radiation 
and the beams are focused through collimators to the target point in the brain. Illustration 
courtesy of Elekta.  
 
4.2.3 Target localization 
4.2.3.1 Study I-III 
In the first patient, treated in 1975, the target coordinates were determined using 
pneumoencephalography. CT localization was employed in 8 operations (65), and two 
were performed with the aid of MRI. Different versions of the Leksell stereotactic 
frame with CT and MRI adaption developed during this period were used.  
The original capsular target according to Leksell, determined with the aid of 
pneumoencephalography was located halfway on the line interconnecting the anterior 
commissure (Ac) and the tip of the frontal horn, i.e. 17-19 mm anterior to the Ac at the 
level of the Ac-Pc (posterior commissure) line. This approximately corresponds to the 
middle portion of the capsule at the level of the posterior part of the medial putamen 
border. Laterality of the targets was 18-20 mm from the midline. When CT scanning 
became available and integrated with stereotactic surgery it was possible for the first 
time to visualize the capsules and the targets were then generally placed a few mm 
more anterior, corresponding to the anterior part of the putamen-capsular border. 
  
4.2.3.2 Study IV 
Target localization, both for thermo- and radiosurgery capsulotomy, was performed 
with the aid of Magnetic Resonance Imaging (MRI) (GE 1.5 T). The Leksell 
stereotactic frame with MRI adaption was used. The target was placed in the anterior 
part of the middle portion of the anterior limb of the internal capsule approximately 
corresponding to the level of posterior part of the medial putamen border. Dorso-
ventrally (the Z-coordinate) the target determination was first performed in an axial 
plane approximately corresponding to the intercommissural plane and was then 
adjusted in a coronal cut so that the intended lesion covered most of capsule, 
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particularly its basal part. For thermocapsulotomy the mediolateral angularity of the 
lesioning electrode trajectory was adjusted to the angle of the capsule as determined in 
the coronal image. 
 
4.3 PSYCHIATRIC METHODS 
4.3.1 Diagnostic methods 
A semistructured interview was the most common diagnostic procedure but for 9 
patients in Study IV, the Structured Clinical Interview for DSM Axis I Disorders 
(SCID-I) interview (66) was used. 
 
4.3.2 Rating scales 
The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) (67) is a widely used scale 
rating the severity of OCD. It consists of 10 items rated from 0 to 4 with 5 items each 
for obsessions and compulsions. A positive response was defined as a ≥ 35% reduction 
in Y-BOCS score from baseline and remission was defined as a Y-BOCS score ≤ 16 
(cf. (14) for a review of response and remission criteria). The Y-BOCS was used in 
Study IV only. In one case the preoperative rating was missing and in 8 patients the 
preoperative rating was done retrospectively at the one-year follow-up.  
 
The Montgomery-Åsberg Depression Rating Scale (MADRS) (68) is a widely used 
depression rating scale with ten items scored from 0 to 6. The Brief Scale for Anxiety 
(BSA) (69) is a rating scale for measuring anxiety symptoms consisting of eight 
reported and two observed items, scored on a 0-6 Likert scale.  
 
Measures of improvement, impairment and global functioning 
Global improvement was measured by the investigator-rated Physician’s Global 
Improvement Scale (PHYGIS) and by the patient on the Patient’s Global Improvement 
Scale (PATGIS) (70). In Study I-III an 11-point Likert scale was used. A score of 10 
indicates maximal improvement. In Study IV a slightly different investigator-rated 
version was used, the Clinical Global Impression–Improvement scale (CGI-I), and the 
Clinical Global Impression–Severity scale (CGI-S) was used as a global measure of 
symptom severity. For the CGI-S, 1 represents “normal, not at all ill” and 7 “amongst 
the most extremely ill of subjects”. For the CGI-I, 1 is the best possible outcome (“very 
much improved”) and 7 the worst (“very much worse”). The Global Assessment of 
Functioning Scale (GAF), i.e. the axis V of the DSM-IV (6), is a composite measure of 
current psychological, social and occupational functioning. Functional impairment was 
evaluated with the 10-point patient-rated work, social life and family life/home 
responsibilities subscales of the Sheehan Disability Scale (71) (0, none; 1-3, mild; 4-6, 
moderate; 7-9, marked; 10, extreme). 
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The Frontal Systems Behavior Scale (FrSBe) (72), formerly known as the Frontal 
Lobe Personality Scale (FLOPS) (73) is a rating scale for the assessment of behavior 
problems associated with damage to the fronto-subcortical brain circuits. The FrSBe is 
a 46-item scale rated on a five-point Likert format. The scale comes in two forms: a 
patient rated and a family rated form comprising the same items. The rating is summed 
to a total score and to subscale scores for executive dysfunctioning (E), apathy (A) and 
disinhibition (D). The questionnaire asks for ratings for two time-points, premorbid (in 
our case preoperative) and current behavior, that is, ratings of preoperative behavior are 
not done preoperatively but rated retrospectively at long-term follow-up. Raw scores 
are transformed to T scores on the basis of gender, education and age. US norms were 
used in the present study. The original version was translated to Swedish and translated 
back to English and the backtranslation was approved by the authors of the scale. This 
scale was used only in Study IV. The scale has been used in research concerning 
neurodegenerative disorders such as Multiple Sclerosis (74), neurosurgical treatment of 
Parkinson’s disease (75), eating disorders (76) and schizophrenia (77).  
 
Execution, Apathy, Disinhibition Scale (EAD Scale) 
For Study I a simple rating scale was constructed, the Execution, Apathy, Disinhibition 
Scale (EAD Scale) because rating scales such as the FrSBe (72) were then not yet 
available. The EAD scale was designed to measure three important functions that have 
been postulated to relate to frontal lobe dysfunction, namely executive dysfunction (E), 
apathy (A) and disinhibition (D). Severity of symptoms was rated on a four-point 
Likert scales (0-3) by two raters on the basis of all information available including 
videotapes of patient interviews and interviews with relatives. Consensus was reached 
for all patients before the scores were entered into the raw data matrix. Patients with a 
total score ≥3 were rated as having clinically significant dysfunction. The group of 
patients with EAD Scale score ≥3 (the EAD group) was compared to the group of 
patients with an EAD Scale score <3 (the non-EAD group). High interrater reliability 
for the EAD scale was demonstrated in Study I. In contrast to the FrSBe, this scale is 
clinician-rated.  
 
4.3.3 The Karolinska Scales of Personality 
The Karolinska Scales of Personality (KSP) is a self-report inventory and comprises 
135 items grouped into 15 scales: anxiety proneness scales, i.e. Somatic Anxiety, 
Muscular Tension, Psychic Anxiety, Psychasthenia, and Inhibition of Aggression; 
extraversion scales, i.e. Impulsiveness, Monotony Avoidance, Detachment, 
Socialization, and Social Desirability; and aggression-hostility scales, i.e. Indirect 
aggression, Irritability, Verbal aggression, Suspicion, and Guilt. Most of the scales are 
based on the hypotheses of biologically relevant temperament dimensions. The KSP 
was used preoperatively, and at one-year and long-term follow-ups. In Study IV, a 
family rated version of the KSP was constructed by substituting all personal pronouns. 
This version was intended to reflect the relatives’ view of the patients personality and 
our aim was to study differences between the patients’ own scoring and that of their 
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relatives. The construction and the psychometric analyses of the KSP have been 
described in detail by Gustavsson (78). The KSP has been revised and the new version, 
the Swedish universities Scales of Personality (SSP) (79), has improved psychometric 
quality. The reason that the KSP was preferred to the SSP in Study IV was that the KSP 
had been used preoperatively.  
 
4.4 NEUROPSYCHOLOGY 
4.4.1 Study I 
A battery of neuropsychological tests (Table 1) was used at long-term follow-up 
comprising tests presumably assessing pre-morbid cognitive function, executive 
functions and short-term working memory, respectively.  
 
Domain Test Function Reference 
Vocabulary MC (WAIS-R NI1) Verbal comprehension and 
semantic memory 
Kaplan,(80)  
Pre-morbid 
level Picture completion (WAIS III2) Visual perception Wechsler,(81) 
COWAT3 (F-A-S) in writing Initiation of word fluency Lezak, (82)  
Executive 
function 
WCST4 Concept formation, shift of  
focus and use of feedback. 
Heaton, (83) 
Digit span (WAIS-R) Verbal short-term memory, 
attention and working memory. 
Wechsler, (84) 
Block span (WAIS-R NI) Spatial short-term memory, 
attention and working memory 
Kaplan,(80) 
 
Short-term and 
working 
memory 
L-N-S5 (WAIS III) Verbal working memory Wechsler, (81) 
 
1 Wechsler Adult Intelligence Test – Revised, as a Neuropsychological Instrument; MC: 
Multiple choice version 
2 Wechsler Adult Intelligence Test III 
3 Controlled Oral Word Association Test 
4 Wisconsin Card Sorting Test 
5 Letter-Number-Sequencing. 
 
Table 1. Functional domains, neuropsychological tests, cognitive functions and references. 
 
4.4.2 Study IV 
Emphasis was given to assessment of executive functions since frontal lobe dysfunction 
is hypothesized to play a role in OCD symptomatology (85) and because results from 
Study I indicated that capsulotomy may be associated with deficits in frontal lobe 
functioning. The chosen tests were selected for reasons of brevity and ease of use as 
well as for their ability to assess both subcomponents of the executive system and 
complex ecologically valid executive behavior. Total duration of neuropsychological 
testing was approximately 1.5 hours. In addition to the abovementioned tests used in 
Study I, the simplified six elements task from BADS (86) (Behavioral assessment of 
the dysexecutive syndrome) was used to assess executive functioning.The last test was 
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used to evaluate the capacity for social insight or the ability to represent thoughts and 
feelings. This choice was based on a case report by Happé (87) describing selective 
deficits in “theory of mind” following capsulotomy. The test consists of 16 short 
stories. Eight of the stories require an answer with an inference about the story 
characters thoughts, feelings and intentions. The eight control stories also require 
reasoning and inference, but the mental states of the characters are not relevant and the 
inference concerns for example physical causation. The first two test in Table 1 were 
not used in Study IV.  
 
Using results from the neuropsychological assessment a global classification of 
dysexecutivity was made for each individual. Results were classified as either not 
showing signs of dysexecutivity (0), showing possible signs (1) and dysexecutive 
neuropsychological function (2). For the classification a cutoff score was identified for 
each of the six neuropsychological subtests of the battery. If two results were below 
cutoff the overall result was classified as indicative of possible dysfunction (1). If three 
or more results were below cutoff the performance was classified as indicative of 
dysexecutivity (2). As three of the tests assessed overlapping attentional and working 
memory aspects of executive function an adjustment was made so that Letter Number 
Sequencing, Digit Span and Visual Span were regarded as one sub-test. This 
classification was done solely on the basis on neuropsychological testing and was done 
independently of the clinical ratings.  
Cutoff scores were: 
 
• FAS: T-score 40 
• Six Elements Task: profile score 4 
• Letter-Number sequencing, Digit Span, Visual Span: cutoff WAIS scale score 7 
• WCST: cutoff less than five categories (64 card version less than three) 
 
For a subset of seven patients pre- to postoperative comparisons regarding WCST and 
span-tests were done.  
 
4.5 NEURORADIOLOGY 
4.5.1 Study I-II 
The imaging study at long-term follow-up was performed with MRI (1.5 T GE Signa 
scanner) that included standard imaging sequences (T1-, proton density-, and T2-
weightings). Slice thickness was 4 mm and interslice gap was 2 mm. A well-
demarcated hyperintense signal change within the anterior limb of the internal capsule 
on proton-weighted sequences was defined as the lesion. The site and extension of the 
lesions were determined according to the same protocol as used in the study by Lippitz 
et al (57). Images were reformatted on the MRI console with an equal angulation 
parallel to the anterior commissure- posterior commissure (Ac-Pc) line as individually 
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defined in all cases. For quantitative interindividual comparison of lesion localization, 
the following anatomical landmarks on the z plane were selected: the anterior 
commissure, the foramen of Monro, and the internal cerebral vein (Figure 9). The 
lesion extent within the internal capsule in the x and y planes was measured in axial 
slices on a superimposed ruler in relation to the adjoining putamen. The part of the 
anterior limb of the internal capsule at the anterio-lateral edge of the putamen was 
assigned to constitute the 0 coordinate, and the capsular part adjacent to the posterio-
medial putaminal edge was defined as the 100 coordinate. In every reformatted MRI 
slice, the start and end points of the lesion were measured on the virtual ruler. The 
values were expressed in percent relative to this virtual ruler, allowing inter-individual 
comparison. The lesion’s site and extension were compared with the right-sided lesions 
reported (57) as being the common topographic denominator of responders: coordinate 
42–64 at the level of the foramen of Monro and coordinate 40–50, 4 mm above on the 
plane defined by the internal cerebral vein. These data were also used to measure 
correlations between lesion extension and outcome. The total lesion area was defined as 
the summed lesioned area determined in the three axial planes. 
 
4.5.2 Study IV 
The imaging study at long-term follow-up was, similarly to Study I-II performed with 
MRI (1.5 T GE Signa scanner) that included standard imaging sequences (T1-, proton 
density-, and T2-weighted images). Slice thickness was 5 mm and interslice gap was 2 
mm. At the last follow-up a detailed MRI study was performed including axial and 
coronal 3D thin-slice imaging, FLAIR, as well as isotropic and anisotropic diffusion 
sequences. The rapid technical evolution of imaging techniques now allows for more 
elaborate studies than were available at the time when the follow-up study was started. 
Methods such as tractography could therefore not be applied to the anisotropic 
diffusion studies. 
 
4.6 STATISTICAL CONSIDERATIONS 
Since sample sizes were small and most variables were non-continuous, generally non-
parametric methods were used. The limited power that was a consequence of the small 
sample sizes is discussed further in section 6.5.2. 
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5 RESULTS 
5.1 STUDY I: CAPSULOTOMY FOR REFRACTORY ANXIETY 
DISORDERS: LONG-TERM FOLLOW-UP OF 26 PATIENTS 
 
Aims 
To assess the long-term efficacy and safety of capsulotomy in 26 consecutive patients 
with non-obsessional anxiety disorders by clinical symptoms ratings and cognitive 
tests. 
 
Sample 
Twenty-six patients who had undergone bilateral thermocapsulotomy were followed up 
after a mean of 13 years. Main diagnoses were Generalized Anxiety Disorder (n=13), 
Panic Disorder (n=8) and Social Phobia (n=5). Seventeen of 23 patients alive at long-
term follow-up were followed-up in person and relatives were interviewed. Of the eight 
patients lost to long-term follow-up, three had died (of suicide, chronic alcoholism, and 
cardiovascular disease, respectively), two were too somatically ill to be interviewed, 
one refused participation, and two patients did not show up. 
 
Efficacy 
Mean preoperative Brief Scale of Anxiety score was 22.0 (SD 5.6), one year 
postoperatively it was 4.6 (SD 4.2), and at long-term follow-up it was significantly 
(p<0.001) lower than at baseline, 9.9 (SD 5.8). There were no significant between-
diagnoses differences. Using a definition of a ≥50 percent reduction in BSA score, 23 
out of 25 were rated as responders at the one-year follow-up. At long-term follow-up 
the responder rate was 12/18.  
The mean preoperative MADRS score was 17.6 (SD 7.4), indicating mild to moderate 
depression (88). At one year postoperatively the MADRS score had decreased to 6.8 
(SD 7.0), and at long-term follow-up to 8.0 (SD 6.8). The changes were significant  
(p< 0.001 and p< 0.01, respectively).  
 
Safety 
Seven patients had EAD scores ≥3, indicative of dysfunction in circuitry involving the 
prefrontal lobe. Examples of poor execution were inability to perform simple 
household tasks such as taking out the garbage, and showing poor judgment. Examples 
of apathy included neglect of hygiene and clothing, lack of initiative, passivity, and 
fatigue. Disinhibition included behavior such as foul language and indecent exposure. 
Two cases of postoperative seizures were recorded. Mean weight gain in the first 
postoperative year was almost 10 kg. The results of the neuropsychological assessment 
are presented in Figure 8.  
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Conclusions 
Thermocapsulotomy is an effective treatment for selected cases of non-obsessive 
anxiety but may carry a significant risk of adverse effects, indicating impairment of 
frontal lobe functioning. Our results underscore the importance of assessments of 
adverse effects carried out face-to-face. 
 
 
 
Figure 8. Performace on neuropsychological tests at long-term follow-up. 
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5.2 STUDY II: LESION TOPOGRAPHY IN CAPSULOTOMY FOR 
REFRACTORY ANXIETY-IS THE RIGHT SIDE THE RIGHT SIDE? 
Aims 
A previous report (57) on bilateral capsulotomy in Obsessive-Compulsive Disorder 
showed common topographic features of lesions in the right-sided internal capsule in 
all patients responding to the treatment. The aims of the present study were to test if the 
same region was involved in anxiety patients responding to surgery and to examine 
whether lesion area and site correlated with adverse effects and effect on target 
symptoms. 
 
Sample 
In this substudy to Study I, the MRI examinations of 11 patients with treatment-
refractory anxiety disorders other than OCD treated with bilateral thermocapsulotomy 
in 1975-1991 were analyzed. 
 
Results 
None of the eight responders had lesions that corresponded to the earlier reported right-
sided anatomical denominator. Four patients out of 11 were rated as having significant 
clinical symptoms indicating frontal lobe dysfunction. The total sum of the lesion area 
determined in each of the three anatomic levels did not correlate with the degree of 
anxiety reduction or ratings of executive dysfunctioning, apathy and disinhibition. 
However, if three of the eleven patients were excluded as being outliers, the lesion area 
may be suggested to be related to the rating of executive dysfunction, apathy and 
disinhibition (Figure 10). 
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Figure 9. Sagittal brain section demonstrating the anatomical landmarks and the three axial 
planes used for the quantitative MRI analysis. Ac: Anterior commissure. Pc: Posterior 
commissure. 
 
 
 
 
Figure 10. Relationship between lesion area and anxiety reduction (a) and adverse effects (EAD 
score) (b). In both figures the Y-axis represents the summed lesion area in the three anatomical 
planes. In Figure 4b the dot marked with a vertical line in the uppermost part of the graph 
represents two patients. 
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5.3 STUDY III: LONG-TERM CHANGES IN SELF-REPORTED 
PERSONALITY FOLLOWING CAPSULOTOMY IN ANXIETY 
PATIENTS 
Aims 
To describe changes in self-reported personality in anxiety patients undergoing 
capsulotomy. 
 
Sample 
Twenty-six consecutive patients with anxiety disorders other than OCD who were 
treated with thermocapsulotomy between 1975 and 1991 at the Karolinska University 
Hospital were included in Study I. Eighteen patients were available for long-term 
follow-up. Sixteen of the 18 patients had complete Karolinska Scales of Personality 
(KSP) sets (preoperatively, at one-year and at long-term follow-up) and constituted the 
sample of the present study. 
 
Results 
Patients were significantly less anxiety prone at long-term follow-up as evidenced by 
the reduction in somatic anxiety (p<0.05) and muscular tension (p<0.05) on the KSP. 
Four patients suffered from adverse effects indicating frontal lobe dysfunction. There 
was no significant correlation between the reduction in BSA score and the KSP change 
from preoperatively to long-term in any of the KSP scales.  
 
Conclusion  
In line with previous studies, high anxiety proneness normalizes after capsulotomy in 
anxiety patients. The adverse effects, described in Study I on the same group of patients 
was not reflected in the KSP. Thus, the conclusion based on previous KSP findings that 
the incidence of adverse personality changes following capsulotomy is low and does 
not increase with time is challenged by the present study.  
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Figure 11. Mean scores in personality scales from the Karolinska Scales of Personality in 
non-OCD anxiety patients before capsulotomy (Pre), one year after the surgery (Post1), and at 
long-term follow-up (Post2). The scores are expressed as differences from the mean T-score 
of a control group of 200 men and 200 women (mean= 50 and SD= 10). 
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5.4 STUDY IV: CAPSULOTOMY FOR OCD: LONG-TERM FOLLOW-UP 
OF 25 PATIENTS 
Aims 
To assess if capsulotomy is effective in reducing obsessive-compulsive symptoms and 
safe. Further to investigate if there are differences in the outcome related to surgical 
method. 
 
Sample 
25 consecutive OCD patients undergoing thermo or radiosurgical capsulotomy. No 
drop out to long-term follow-up except for two deceased (one of homicide and one of 
suicide). 
 
Results 
Mean Y-BOCS was 34 preoperatively and dropped to 18 at long-term follow-up 
(p<0.0001). Twelve patients responded (≥35 % Y-BOCS reduction) and eight were in 
remission (Y-BOCS<16) at long-term follow-up. The scores of depression and anxiety 
ratings were also significantly lower at long-term follow-up (Figure 12). Only 2 
patients achieved remission from OCD without substantial side effects. Several 
neurosurgical complications related to radiosurgery were reported. A mean weight gain 
of 6 kg was reported in the first postoperative year (p<0.001). Two patients were 
severely disinhibited postoperatively. Ten patients were considered to suffer from 
significant problems in the area of executive functioning, apathy or disinhibition.  
 
Fourteen patients were classified as dysexecutive at long-term follow up based on 
neuropsychological testing. In all these cases dysfunctioning was manifested in at least 
three tests. In seven patients a comparison of pre- and postoperative tests indicated a 
worse performance postoperatively in tests of executive functions. Of the ten patients 
that were rated as showing clinically significant signs of executive dysfunctioning, 
apathy or disinhibition, eight also were classified as neuropsychologically impaired. 
 
In a preliminary analysis of the lesion size in 21 patients, the mean size of right sided 
lesion was 2494 mm3 (SD 4731, range 463-22756) and of the left sided lesion 3981 
mm3 (SD 6035, range 460-25170). Lesion size did not correlate significantly with 
efficacy (percentage of Y-BOCS reduction, r=0.17) or total EAD score (r=-0.29) 
(Figure 13).  
 
Conclusions 
Capsulotomy is effective in reducing OCD symptoms but carries a significant risk of 
substantial side effects.  
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Figure 12. Symptom rating mean scores preoperatively, at 1-year and long-term follow-up. 
 
 
Figure 13. Right sided lesion size (Y-axis) and EAD total score (X-axis). The patient (id 20) with 
the largest lesion (22756 mm3) was excluded from the display. 
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6 DISCUSSION 
The aim of this thesis was to evaluate the long-term safety and efficacy of capsulotomy 
in anxiety disorders (Study I-III) and OCD (Study IV). 
 
6.1 IS CAPSULOTOMY EFFECTIVE IN TREATING ANXIETY AND OCD? 
6.1.1 The efficacy 
In our two long-term follow-up studies of anxiety and OCD patients who had 
undergone capsulotomy, symptom reduction at both one-year and long-term follow-ups 
was significant. The symptom improvement must be considered impressive given the 
severity and chronicity of the patients’ illness. The magnitude of the improvement is in 
line with standard treatments for anxiety disorders such as SSRIs and CBT (89, 90) and 
with previous capsulotomy studies (53, 56, 58).  
  
6.1.2 Why isn’t global functioning improved? 
The global function as measured by the GAF does not show any substantial 
improvement in Study IV. A return to a normal functioning with for instance 
employment was hardly ever seen. In Study III, GAF had only been rated at long-term 
follow-up but was in line with the results of Study IV. Another study (58) found a 
strikingly similar postoperative GAF score. The long duration of illness in almost all 
patients should be taken into account. It may be extremely difficult to return to work 
from disability pension even if symptoms subside. It may also be that the long duration 
of illness had induced dysfunctional behavioral patterns not specific to illness that 
linger after symptom relief. However, in Study IV, the self-rated social disability rated 
with the Sheehan Disability Scale showed marked improvement.  
 
My personal impression that includes insights from home visits and talking to the 
patient’s relatives is that there was impairment in general functioning at long-term that 
was not explained by neither anxiety nor obsessive-compulsive or depressive 
symptoms but rather related to drive and motivation. Autism spectrum disorders such 
Asperger’s syndrom have a high comorbidity with OCD (91). Undetected comorbidity 
with these disorders could in some cases be an explanation for the low global 
functioning at long-term follow-up. Another speculation would be that the remaining 
dysfunction is a remainder of OCD, much like negative symptoms in schizophrenia that 
the surgical intervention does not alleviate.  
 
6.1.3 Which surgical method is the most effective? 
Most patients included in this thesis were subjected to conventional thermosurgery. In 
Study IV, 9 patients underwent radiosurgery. Within the radiosurgery group there was 
considerable variation in the surgical method, that is, five patients received 
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exceptionally high doses of radiation and of these three cases the patients developed an 
adverse radiation reaction. Therefore, our radiosurgery sample is not comparable to 
those studies where other doses have been used. In the capsulotomy series performed at 
Brown University, Rhode Island, 180 Gy at two isocenters bilaterally is used (Georg 
Norén, personal communication), a dose considerably lower than what some of our 
patients received. We could not find any significant difference between radiosurgery 
and thermosurgery but given the small sample sizes and the variation within the group 
it is not possible to draw any general conclusion about the differential efficacy of the 
methods.  
 
The mean Y-BOCS reduction from baseline to long-term follow-up was 47% in Study 
IV. In a recent long-term follow-up of cingulotomy (13), the corresponding figure was 
29%. Kullberg reported a case series including both cingulotomy and capsulotomy 
cases and the efficacy of capsulotomy was higher (59). However, without a randomized 
head-to-head comparison between capsulotomy and cingulotomy, it is not possible to 
draw a firm conclusion on the differential efficacy of the methods.  
 
We could not find any correlation between lesion size and symptom reduction in either 
of our studies. The two patients in Study IV that had the largest lesions, (Id 17 and 20) 
had a Y-BOCS score of 15 and 27 at long-term follow-up, indicating that even very 
large lesions can sometimes fail to relieve the patient from OCD.  
 
6.1.4 Effect over time 
After the first postoperative year there was generally no further improvement in neither 
of the samples. A report by Kihström et al (63) showed that the tissue reaction volume 
after radiosurgery may still be increasing after 3 years, suggesting that there may be late 
effects of the treatment. This was not observed in Study IV since the radiosurgery 
patients that responded did so already at the one-year follow-up. Our conclusion 
therefore is that, in contrast to an earlier report (92), improvement is generally 
maintained over time. 
 
6.1.5 Are there differences across diagnoses? 
Due to the small number of patients in each diagnostic group, any comparison between 
groups will be severely underpowered. Given this very important limitation, we found 
no difference between diagnoses. In the OCD patients of Study IV it could be 
speculated that the effect on the OCD symptomatology is not a direct effect on OCD 
but rather secondary to anxiety reduction, that makes obsessive intrusions less prone to 
evoke a behavioral response. The fact that capsulotomy is used for both depression, 
anxiety disorders and OCD may be an indication that the effect is not that specific. This 
efficacy across diagnostic boundaries is something that NMD shares with other, more 
common treatments such as the SSRIs. 
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6.1.6 What would the outcome have been without surgery? 
In their unique 40-year follow-up, Skoog & Skoog (93) followed the course of OCD 
patients, originally assessed in the 1950s. Most of the patients improved over time and 
recovery was common. A similar pattern of recovery was seen in the Zurich study by 
Angst et al (94). Mataix-Cols and collegues (95) studied the temporal stability of 
individual OCD symptoms over 2 years and concluded that most patients maintained 
the symptoms and if symptoms changed they remained within the same symptom 
dimension. It is important to take into consideration the possibility that patients may 
improve even without treatment. On the other hand, patients, almost without exception, 
said at long-term follow-up that they would choose surgery again, indicative of their 
own estimation of their poor prognosis. The preoperative clinical impression in our 
studies, given the chronic state of the patients with illness duration of 20 years and 
more, was that no remission was in sight without treatment. 
 
Due to the severity of the illness and the associated risk of suicide some have argued 
that patients would risk suicide if they were denied surgery. There has been some 
controversy as to whether anxiety disorders are independently associated with suicide 
risk or if the risk rather is associated with comorbid mood disorder. It has now been 
demonstrated that anxiety disorders are an independent risk factor for suicidal ideation 
and attempts (96). Anxiety patients have also been shown to be at greater risk for 
suicide than the normal population (97-99), but probably less at risk than depressed 
patients. In our studies the rate of patients that had made suicide attempts was similar 
before and after surgery. Two patients committed suicide postoperatively. Therefore, 
our studies do not provide support for a vital indication for surgery.  
 
6.2 IS CAPSULOTOMY SAFE? 
The majority of the patients did not experience any side effects. At the same time, we 
encountered more adverse effects of capsulotomy in our two samples than expected 
from the literature (55, 56, 60). Seventeen of totally 51 patients (33%) had executive 
problems, apathy or disinhibition. Not only were these adverse effects common, they 
also severely impacted functioning. The most common side effect was apathy and 
executive dysfunctioning whereas only a few patients developed disinhibition. Other 
complications were weight gain, epilepsy and urinary incontinence. Similar types and 
frequencies of adverse effects were seen in both anxiety and OCD patients. Adverse 
radiation reactions were obviously only seen in the OCD sample since radiosurgery 
was only applied in Study IV. We thus have to conclude that capsulotomy is not a safe 
procedure.  
 
6.2.1 Is radiosurgery safer than conventional surgery? 
Radiosurgery is non-invasive surgery, probably coming across as more “modern” than 
conventional surgery but is not safer per se. It is not meaningful to discuss the 
differences between surgical methods without taking lesion size into account. In both 
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the radiosurgery and the thermocapsulotomy group there was considerable variation 
within the surgical method, i.e. size of the intended thermolesion or radiation dose, 
leading to expected differences in lesion sizes. Radiosurgery may be a safer procedure 
at other radiation doses than those we used or with refined accuracy in lesion 
placement. Nevertheless, it is important to notice that large lesions does not explain 
why certain individuals had adverse effects and others not. Some patients were 
surprisingly intact after very large lesions whereas other had severe side effects after 
normal or even small lesions. 
 
6.2.2 Why do some patients develop side effects and others not? 
There is a large variation in how patients reacted to the lesioning in our samples of 
totally 51 patients. To be able to avoid future complications, it is essential to understand 
why some patients suffered from severe side effects while others were unaffected. The 
analysis of the characteristics of the surgical lesion has not yet been fruitful in 
explaining this. A further analysis of lesion localization is in preparation, which 
hopefully can provide the necessary answers. The side effects were seen across 
diagnosis and surgical method. Preoperative neuropsychological examination was only 
available in a few patients, therefore we do not know for certain if some patients may 
have been more vulnerable due to pre-existing cognitive problems. 
 
6.2.3 Some comments on the assessment of side effects 
6.2.3.1 KSP - normalization of personality? 
In a study by Mindus and colleagues (100), 19 patients were studied before 
capsulotomy for OCD and at 1- and 8-year follow-up. The main finding was changes 
towards normalization on all 15 KSP scales at 1-year follow-up and significant 
reductions in anxiety proneness at the 8-year follow-up. Significant reductions in 
aggression-hostility, indirect aggression and guilt were observed at 8-year follow-up. 
The authors conclude, “adverse personality changes are not to be expected even many 
years after the operation”. This normalization of self-reported personality after 
capsulotomy has been used (3, 60) as an argument for the safety of capsulotomy. 
However, the results have been challenged (2) as the validity of self-reported 
personality inventories in measuring adverse frontal events has not been proven. One of 
our main findings was that adverse effects on personality were clinically obvious 
despite “improvement” on the KSP on a group level. The type of personality changes, 
that were most incapacitating, namely those indicative of impaired frontal lobe 
functioning, are not within the scope of the KSP. Furthermore, the lack of insight which 
characterized some of our patients is likely to impair the validity of a self-assessment 
instrument such as the KSP. In our analysis of family and self-rated KSP in Study IV, 
there were large variations across different scales in the KSP in the correlation between 
family and self-rating. There was a good agreement on many scales including the 
anxiety related scales but poor correlation between the raters on scales such as the 
Psychastenia, Irritation and Socialization scales. 
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6.2.3.2 Face-to-face examinations 
When Gösta Rylander did his research on patients with frontal lobe damage (40), he 
based his results on a thorough examination, including an astonishingly advanced 
neuropsychological assessment, but also on observations made during visits in the 
patients’ homes. He even hired one lobotomy patient as a cook, although she “had 
difficulties in using new recipes and made ridiculous mistakes”(42). Rylander’s 
personal observations added something to his testing and his characterization that a 
patient had “lost his soul” became despite its subjectiveness a very important argument 
against the indiscriminate use of lobotomy by Walter Freeman and others (38). In the 
spirit of Rylanders work, I would like to emphasize the importance of multimodal face-
to-face evaluations that can take aspects of the patient’s mental state into account that 
e.g. telephone follow-ups will miss.  
 
6.2.3.3 Relatives – a window into our patients’ world 
For our studies, it turned out to be important that we interviewed the patients’ relatives. 
The case report 1 in Study I is an example. When I asked this man, who now was 
considerably better in his anxiety disorder, what he did during the day he told me that 
he read books and watched TV. When I asked his wife the same question she told me 
“Oh, he reads the same book every day since 10 years!” It turned out to be a book for 
kids about cats.  
 
6.2.3.4 Neuropsychological testing 
In Study I only postoperative testing was available and results showed subnormal 
results, especially in the patients that displayed clinical signs of executive disfunction 
and apathy. Fourteen patients in Study IV were classified as dysexecutive at long-term 
follow up based on neuropsychological testing. Our sample was characterized by more 
pronounced neuropsychological deficits than in most OCD samples reported  
(101, 102). Interestingly, symptom severity in OCD has not been shown to be 
correlated to neuropsychological functioning (101) and there might therefore be other, 
unknown characteristics of our sample that explain the severity of the 
neuropsychological impairment. Executive dysfunction has not consistently been 
observed in OCD patients compared to normal controls (101, 102).  
 
The possibility of pre- and postoperative comparisons was limited since only a minority 
of the patients in Study IV and none in Study I were adequately assessed before the 
operation. A comparison in seven patients indicated a worse performance 
postoperatively in tests of executive functions. Nyman et al (103, 104) have reported 
neuropsychological test results in both capsulotomy patients and patients on waiting list 
for capsulotomy. Our findings were in line with the previous findings regarding 
postoperative performance in capsulotomy (103-105). In the pre- vs. postoperative 
comparison in the small study of Nyman et al (104) a subgroup had more perseverative 
errors in the WCST. In Study IV, the reduction of OCD symptoms was not 
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accompanied by an improvement in executive performance. Similar lack of 
correspondence between neuropsychological functions and symptom improvement has 
been observed with other forms of treatment (106).  
 
6.2.4 Other studies did not report safety problems 
Most other capsulotomy studies (55-58, 60, 107) did not report the same side effect 
frequency. We can only speculate why that may be. It may be that our patients had 
some, for us unknown feature that made them especially vulnerable to develop side 
effects and thus, that the same safety problems are not to be encountered in other case 
series. However, it is not evident that our patients are different from other samples. It 
may also be speculated that there was something in the surgical method that was used 
at our site that resulted in differences in lesions from others sites. Unfortunately, there 
is a lack of published reports on the outcome from other sites, therefore this question 
cannot be resolved at this time. It may be that the multimodal face-to-face follow-up 
that we used was more sensitive to identify adverse effects that others have missed. A 
systematic evaluation of potential safety problems appears essential in studies of 
neurosurgery for mental disorders. 
 
6.3 INTO THE GARDEN OF GOOD AND EVIL: ETHICAL 
CONSIDERATIONS 
6.3.1 Burckhardt’s dilemma 
The possibility of symptom relief and adverse effects takes us back to the first 
“psychosurgeon” Gottlieb Burckhardt who already in 1891 was caught between the 
Melius anceps remedium quam nullum (Better an uncertain remedy than none at all) 
and the more cautious Primum non nocere (First, do no harm). Clearly, there is no easy 
answer since withholding even a potentially dangerous treatment comes with the price 
of missing the possible benefit of the treatment. To make things harder, patients with 
the most pronounced change in personality (i.e. disinhibition) stated that they had never 
been better and one patient even claimed to have found her true self. 
 
6.3.2 Who decides? 
If the disinhibited patient, whose behavior clearly makes her relatives suffer, claims 
that she does not have any symptoms and is feeling well, who is to decide on the 
general outcome of her treatment? Autonomy is a widely cherished ideal and in its 
most restricted meaning it is about self-determination. Living an autonomous life is to 
live according to our own wishes, desires and according to our own ideas of a good life. 
In that sense, patients that have become disinhibited after surgery can still be 
considered to be autonomous, probably even more so than before surgery. This 
conceptualization of autonomy does not contain in itself any idea of what an ideal or 
moral life is, since self-determination per se does not imply good, or for that matter 
evil. A pedophile could be conceptualized as very autonomous. To make autonomy 
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useful in this context, the capacity to make decisions and understand their 
consequences for others must be taken into account. For a more educated discussion on 
what autonomy is and is not, cf. (108). Personally, I agree with John Donne who in 
1624 (109) captured the essence of this issue:  
 
 
No man is an island, entire of itself 
every man is a piece of the continent, a part of the main 
 
 
6.3.3 Informed consent 
In the past, psychosurgery occasionally has been used as an involuntary treatment. 
Today we regard this as an abuse, even if the outcome in a specific patient was 
beneficial. Nowadays, patients give their informed consent to neurosurgical procedures 
such as capsulotomy. Nevertheless, we cannot simply assume that patients are capable 
to consent just because they are willing to undergo the treatment (110). Having the 
capacity to consent must include basic mental skills and therefore a child or a mentally 
retarded patient would not be considered eligible for surgery. Informed consent 
obviously requires that the patient has obtained correct information about the possible 
risks and benefits of a procedure. Autonomy is a prerequisite for free choice (110, 111). 
Consenting to capsulotomy is making a choice, and in this particular case a choice that 
irreversibly alters brain functioning. Now, consider a severely ill OCD patient that has 
tried all available treatment to no avail, is she free to choose when considering 
capsulotomy, that is, has she the choice of different options? Or is the desperate patient 
impaired in her capacity to give an informed consent? This is a common problem in 
many other medical conditions, such as cancer or chronic pain, where the patient’s 
choice is limited by his or her illness. Another complication is that, if who we are is 
changed after a treatment, even if it’s for the better, how is the patient then able to 
evaluate this change? Even if we can’t answer these difficult questions, in clinical 
practice, these are the questions that we should be aware of when discussing the 
treatment with patients.  
 
6.3.4 Compassion and the unusual ones 
Severe and treatment refractory illness often calls for desperate measures. 
Pharmacological treatment options are more regulated than medical devices and 
surgery since extensive legislation is limiting its use. There is a risk that compassionate 
use of methods for unusual patients is not followed by proper evaluation. I would argue 
that it is especially important in severe illness and in unusual treatments such as 
capsulotomy to ensure that scientific evidence is gathered. The desperate situation of 
the patients and our own compassion cannot let us make an exception from this rule. To 
conclude, all centers performing neurosurgery for mental disorders must include their 
patients in studies that can contribute to a more solid evidence base for the methods. 
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The paucity of published reports in recent years, indicate that more could be done to 
gather further evidence. 
  
6.4 NEUROANATOMICAL CONSIDERATIONS 
6.4.1 Are the side effects related to a certain type of lesion? 
In Study II we tried to find correlates of the anterior-posterior lesion location and the 
outcome without success. In neither Study II nor IV we could find firm evidence for a 
relationship between lesion size and side effects. It is our hope that further analysis of 
the MRI data on both the axial and the coronal planes in Study IV can bring some light 
into the optimal lesion placement. There were large differences between the patients’ 
side effects pointing towards an effect on different parts of the prefrontal cortex. 
Interindividual variation in the wiring of the internal capsule could also contribute to 
the differences in vulnerability.  
 
6.4.2 Was the right side the right side? 
Previous research (57) indicated that a certain right-sided capsulotomy lesion was a 
prerequisite for treatment response in OCD. This hypothesis did not prove to be correct, 
at least not in non-OCD anxiety, and given the variability in lesion placement as 
evidenced by Study II the validity of the previous findings is unclear. As for the OCD 
patients of Study IV, we await further analysis of the lesion site. Four patients in Study 
IV underwent unilateral right-sided thermocapsulotomy but the results failed to impress 
since the one of the four who was in remission at long-term follow-up instead was 
incapacitated by somatoform symptoms, living in a nursing home.  
 
6.4.3 Next stop: ventral striatum? 
Based on a possible role of the nucleus accumbens in OCD and the clinical impression 
that ventrally placed capsulotomy lesions are more effective, Sturm et al (28) 
stimulated four patients with Deep Brain Stimulation (DBS) in the right-sided nucleus 
accumbens with promising results. Despite interesting theoretical reasons and a clinical 
impression, there is no published evidence on where in the dorso-ventral plane of the 
anterior capsule the surgeon should place the lesions. The only way to gain empirical 
evidence is to systematically study the lesions and the outcome and we aim to 
contribute to that with a future analysis of the lesions in the coronal plane in Study IV. 
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6.5 LIMITATIONS 
6.5.1 Evaluation bias 
The studies were not randomized-controlled trials, a fundamental weakness shared with 
all other NMD studies to date. Some of the other potential biases encountered in some 
earlier (cf page 10) studies were avoided since the principal author was not involved in 
preoperative treatment of the patients and he did not select patients for surgery. Another 
strength of these studies is that data loss was limited and that face-to-face interviews 
with patients and their relatives were performed. 
 
6.5.2 Power 
The relatively small sample sizes yield a low power to detect small and medium sized 
differences. This is an inherent problem in studies of infrequent treatments. Fortunately, 
we found very significant improvements in our primary outcome measures and the 
power issue does not weaken these findings.  
 
6.5.3 Regression towards the mean 
The regression towards the mean effect (112) is the phenomenon that a variable that is 
extreme on its first measurement will tend to be closer to the center of distribution for a 
later measurement. This is particularly important in non-randomized medical trials that 
use inclusion criteria such as a high symptom score. Waxing and waning of symptoms 
will also contribute to this effect. In our studies we only included patients with severe 
symptomatology, therefore the reduction at later follow-ups may to some extent be 
attributable to the regression towards the mean effect.  
 
6.5.4 Rating scales 
Most of the Swedish versions of the rating scales had not been validated and the EAD 
scale was constructed for Study IV and its psychometric properties are not known.  
 
6.5.5 Preoperative data incomplete 
Some important preoperative data, e.g. neuropsychological testing, in missing to a 
various extent in the studies. This was an inevitable consequence of the long-term 
follow-up study design but nevertheless limits the conclusivity of the 
neuropsychological results.  
 
6.5.6 Causality 
The long follow-up period will for each patients include many life events, in some 
cases comorbid disorders and other events that will affect the outcome at long-term 
follow-up. A temporal relationship between the surgical intervention and the state of 
the patient should therefore not be confused with a causal relationship.   
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7 MS. A AND MS. S: WHAT HAPPENED? 
 
Ms. A 
Feeling increasingly desperate, she took the initiative to be evaluated for 
capsulotomy, which was performed at age 40. At the two-month follow-up most 
avoidance behavior had dissipated and she needed no medication. Within a year she 
was back at her old job and reported that her social anxiety “was a closed chapter”. 
At long-term follow up, at age 52, she reports leading a life without limitations and 
states, “without the operation I wouldn’t be alive today”. Her anxiety symptoms were 
gone and there were no adverse effects of the procedure.  
 
Ms S 
At age 50, after evaluation and approval for capsulotomy, she became, to our 
knowledge the world’s first OCD patient to undergo Deep Brain Stimulation. The 
treatment was unsuccessful, electrodes were extracted and she went on to have a 
bilateral thermocapsulotomy. After initial improvement her OCD worsened and was 
was back to baseline severity at long-term follow-up. She gained almost 20 kg in her 
first postoperative year and has persistent urinary incontinence. Intensive trials both 
with pharmacological and psychological treatment have had modest effects. Her 
relatives describe her as apathetic and displaying lack of initiative. Ms S makes no 
effort to resist the obsessive intrusions. Neuropsychological evaluation confirms a 
decline in executive functioning.  
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8 GENERAL CONCLUSIONS 
a. Capsulotomy is effective in reducing symptoms in both OCD and other anxiety 
disorders. Global functioning did not return to normal after surgery but the 
evidence suggests that most patients will remain incapacitated. Self-rated 
anxiety proneness and depressive symptoms decreases after surgery. 
b. About every third patient experienced apathy, executive problems or 
disinhibition at long-term follow up. Other adverse effects reported included 
epileptic seizures, urinary incontinence and weight gain. Capsulotomy is not a 
safe procedure. 
c. We could not identify lesion characteristics that could explain the differences in 
outcome. We could not confirm the hypothesis of a certain right-sided lesion as 
a prerequisite for treatment response. 
d. Interviews with the patients’ relatives are crucial to correctly identify potential 
adverse effects of surgery. 
e. In the light of its potential adverse effects and the limited evidence of the 
procedure, capsulotomy clearly needs to be studied more extensively. Until 
such studies are at hand, NMD procedures should only be performed within 
study protocols and are preferably regarded as experimental treatments.  
 
8.1 WHAT NOW? FUTURE DIRECTIONS 
Since OCD is the main indication for NMD, this will likely be the focus of future 
research in this field. As evidenced by the studies of this thesis, capsulotomy is 
followed by unacceptably high risks of adverse effects. These adverse effects are often 
permanent. There is yet no evidence on how ablative NMD can be made safe. A 
method that is reversible would therefore be preferable. One such method is Deep 
Brain Stimulation, were electrically stimulated electrodes are implanted in the brain.  
There are several centers currently implanting DBS devices in OCD patients and the 
question of optimal lesion placement is central to the development in this field. We 
hope that further analysis of the lesion topography in Study IV, especially in the dorso-
ventral direction, can elucidate this issue regarding both the positive and negative 
effects. Certainly, DBS is to be preferred over ablative NMD from a safety standpoint 
even though only very limited information is at hand on the safety of DBS in OCD. 
Further research should also explore non-surgical treatment options such as intensive 
CBT programs, something that was unavailable preoperatively to the patients of this 
thesis. Neurosurgery also provides a unique opportunity to study brain and behavior. 
Hopefully, more sophisticated techniques and hypotheses in the future can derive 
insights from these treatments that can eventually be helpful to the patients.   
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